Study of O-sialylation of glycoproteins in C6 glioma cells treated with retinoic acid.
When treated with retinoic acid in vivo, C6 glioma cells show an enhancement of CMP-Neu5Ac:Gal beta 1-3 GalNAc-R alpha-2,3 sialyltransferase activity. A 300 kDa glycoprotein was detected by lectin affinoblotting in retinoic acid-treated C6 cells which stained weakly or not at all in control cells. Comparative studies with different lectins demonstrated that this glycoprotein contains alpha 2,3 Neu5Ac Gal-GalNAc O-glycan moieties. Cultures in the presence of an inhibitor of O-glycan synthesis (N-acetylgalactosaminide alpha-O-benzyl) demonstrated that enhancement of staining of the 300 kDa glycoprotein was not due to the increase of the alpha 2,3 sialytransferase but to the de novo synthesis of the polypeptide chain of this glycoprotein.
Reboul
P
P
Laboratorie de Biochimie Geńale et Médicale, INSERM-CNRS U.189, Faculté de Médecine Lyon-Sud, Oullins, France.
George
P
P
Miquel
D
D
Louisot
P
P
Broquet
P
P
D000818:Animals; D002240:Carbohydrate Sequence; D005910:Glioma / Q000378:metabolism; D006023:Glycoproteins / Q000737:chemistry / Q000378:metabolism*; D008969:Molecular Sequence Data; D051381:Rats; D018168:Receptors, Retinoic Acid / Q000378:metabolism; D012795:Sialoglycoproteins / Q000737:chemistry / Q000378:metabolism*; D012799:Sialyltransferases / Q000378:metabolism; D014212:Tretinoin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured; D000094663:beta-Galactoside alpha-2,3-Sialyltransferase
D006023:Glycoproteins; D018168:Receptors, Retinoic Acid; D012795:Sialoglycoproteins; D014212:Tretinoin; D012799:Sialyltransferases; D000094663:beta-Galactoside alpha-2,3-Sialyltransferase